Sigrid Carlsson, MD, PhD, MPH

Director of Clinical Research, Josie Robertson Surgery Center; Assistant Attending Epidemiologist
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Departmental Newsletter
Career Opportunities
Quantitative Sciences Undergraduate Research Experience (QSURE)
Genomics Experience for Master’s Students (GEMS)
Software
Bridge to Biostats Programs

Sigrid Carlsson, MD, PhD, MPH

Director of Clinical Research, Josie Robertson Surgery Center; Assistant Attending Epidemiologist
Share
Share
Sigrid Carlsson, MD, PhD, MPH Assistant Attending Epidemiologist

Office Phone

646-888-8250

Email

[email protected]

Education

MD, PhD, Gothenburg University; MPH, Harvard T.H. Chan School of Public Health

Current Research Interests

Dr. Carlsson is Director of Clinical Research at MSK’s Josie Robertson Surgery Center and Assistant Attending Epidemiologist, with dual appointments in MSK’s Departments of Surgery (Urology Service) and Epidemiology and Biostatistics. Her line of research focuses on screening and early detection of prostate cancer, including multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging, as recently funded by a NCI U01 award (PI: Carlsson). She also holds an appointment as Associate Professor of Experimental Urology affiliated with the Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, in Sweden where she is an investigator of two large randomized controlled trials of prostate cancer screening (GOTEBORG-1&2), as recently published in the New England Journal of Medicine (Hugosson J, et al. N Engl J Med 2022; 387:2126-2137). She recently completed a K22 career development award from the NCI to improve shared decision making for breast and prostate cancer screening. She serves on the NCCN and AUA guidelines for early detection of prostate cancer.

Publications

Selected peer-reviewed publications:

  1. Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L, Geterud K, Khatami A, Kohestani K, Pihl CG, Socratous A, Stranne J, Godtman RA, Hellström M; GÖTEBORG-2 Trial Investigators. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med. 2022 Dec 8;387(23):2126-2137.
  2. Carlsson SV, Arnsrud Godtman R, Pihl CG, Vickers A, Lilja H, Hugosson J, Månsson M. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2022 Nov 2:S0302-2838(22)02715-4.
  3. Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ. 2014 Mar 28;348:g2296.
  4. Carlsson S, Benfante N, Alvim R, Sjoberg DD, Vickers A, Reuter VE, Fine SW, Vargas HA, Wiseman M, Mamoor M, Ehdaie B, Laudone V, Scardino P, Eastham J, Touijer K. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. J Urol. 2020 Jun;203(6):1122-1127.
  5. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010 Aug;11(8):725-32.

View a full listing of Sigrid Carlsson’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sigrid Carlsson discloses the following relationships and financial interests:

  • American Urological Association
    Provision of Services (uncompensated)
  • Australian Prostate Centre
    Provision of Services (uncompensated)
  • BJU International
    Provision of Services
  • European Association of Urology
    Provision of Services
  • Grand Rounds in Urology
    Provision of Services (uncompensated)
  • Mediahuset i Goteborg AB
    Provision of Services
  • National Comprehensive Cancer Network
    Provision of Services (uncompensated)
  • The Chinese University of Hong Kong
    Provision of Services
  • The Journal of Sexual Medicine
    Provision of Services
  • Urological Society of Australia and New Zealand (USANZ)
    Provision of Services (uncompensated)
  • Weill Cornell Medicine
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures